BioAlliance Pharma Obtains European Approval for Loramyc Tablet Embossing and Extension of Its Shelf Life to 36 Months

13-Jul-2009 - France

BioAlliance Pharma SA announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis.

The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance Pharma submitted a new drug application for Loramyc® to the Food and Drug Administration (FDA) in June 2009. BioAlliance Pharma will be able to harmonize Loramyc® production within those two key markets.

BioAlliance Pharma also received European approval for extension of Loramyc®'s shelf life from 18 to 36 months.

These two key industrial parameters are complementary assets for Loramyc® and will help optimizing manufacturing, storage and distribution costs.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?